Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells

被引:26
作者
Fediuc, S. [1 ]
Pimenta, A. S. [1 ]
Gaidhu, M. P. [1 ]
Ceddia, R. B. [1 ]
机构
[1] York Univ, Dept Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada
关键词
D O I
10.1002/jcp.21321
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The aim of this study was to investigate the acute effects of troglitazone on several pathways of glucose and fatty acid (FA) partitioning and the molecular mechanisms involved in these processes in skeletal muscle. Exposure of L6 myotubes to troglitazone for 1 h significantly increased phosphorylation of AMPK and ACC, which was followed by similar to 30% and similar to 60% increases in palmitate oxidation and carnitine palmitoyl transferase-1 (CPT-1) activity, respectively. Troglitazone inhibited basal (similar to 25%) and insulin-stimulated (similar to 35%) palmitate uptake but significantly increased basal and insulin-stimulated glucose uptake by similar to 2.2- and 2.7-fold, respectively. Pharmacological inhibition of AMPK completely prevented the effects of troglitazone on palmitate oxidation and glucose uptake. Interestingly, even though troglitazone exerted an insulin sensitizing effect, it reduced basal and insulin-stimulated rates of glycogen synthesis, incorporation of glucose into lipids, and glucose oxidation to values corresponding to similar to 30%, similar to 60%, and 30% of the controls, respectively. These effects were accompanied by an increase in basal and insulin-stimulated phosphorylation of Akt(Thr308), Akt(Ser473), and GSK3 alpha/beta. Troglitazone also powerfully suppressed pyruvate decarboxylation, which was followed by a significant increase in basal (similar to 3.5-fold) and insulin-stimulated (similar to 5.5-fold) rates of lactate production by muscle cells. In summary, we provide novel evidence that troglitazone exerts acute insulin sensitizing effects by increasing FA oxidation, reducing FA uptake, suppressing pyruvate dehydrogenase activity, and shifting glucose metabolism toward lactate production in muscle cells. These effects seem to be at least partially dependent on AMPK activation and may account for potential acute PPAR-gamma-independent anti-diabetic effects of thiazolidinediones in skeletal muscle.
引用
收藏
页码:392 / 400
页数:9
相关论文
共 32 条
[21]   A POTENT INVIVO EFFECT OF CIGLITAZONE ON MUSCLE INSULIN RESISTANCE INDUCED BY HIGH-FAT FEEDING OF RATS [J].
KRAEGEN, EW ;
JAMES, DE ;
JENKINS, AB ;
CHISHOLM, DJ ;
STORLIEN, LH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (11) :1089-1093
[22]   Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues [J].
LeBrasseur, Nathan K. ;
Kelly, Meghan ;
Tsao, Tsu-Shuen ;
Farmer, Stephen R. ;
Saha, Asish K. ;
Ruderman, Neil B. ;
Tomas, Eva .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 291 (01) :E175-E181
[23]   ACUTE EFFECTS OF TROGLITAZONE ON IN-VIVO INSULIN ACTION IN NORMAL RATS [J].
LEE, MK ;
OLEFSKY, JM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (09) :1166-1169
[24]   METABOLIC EFFECTS OF TROGLITAZONE ON FRUCTOSE-INDUCED INSULIN-RESISTANCE IN THE RAT [J].
LEE, MK ;
MILES, PDG ;
KHOURSHEED, M ;
GAO, KM ;
MOOSSA, AR ;
OLEFSKY, JM .
DIABETES, 1994, 43 (12) :1435-1439
[25]   Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes [J].
McGarry, JD .
DIABETES, 2002, 51 (01) :7-18
[26]   Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance [J].
Miles, PDG ;
Higo, K ;
Romeo, OM ;
Lee, MK ;
Rafaat, K ;
Olefsky, JM .
DIABETES, 1998, 47 (03) :395-400
[27]   Regulation of glycogen synthase activity and phosphorylation by exercise [J].
Nielsen, JN ;
Wojtaszewski, JFP .
PROCEEDINGS OF THE NUTRITION SOCIETY, 2004, 63 (02) :233-237
[28]   Troglitazone - A review of its use in the management of type 2 diabetes mellitus [J].
Plosker, GL ;
Faulds, D .
DRUGS, 1999, 57 (03) :409-438
[29]  
RANDLE PJ, 1963, LANCET, V1, P785
[30]   SUBSTITUTED 2-OXIRANECARBOXYLIC ACIDS - A NEW GROUP OF CANDIDATE HYPOGLYCEMIC DRUGS [J].
SELBY, PL ;
SHERRATT, HSA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (12) :495-500